ResearcherImmunomedics (United States)No recent work listed
William A. Wegener
Matched on OpenAlex author ID A5014083764. Sources: ClinicalTrials.gov.
Their work
- Papers
- 2
- Trials
- 5
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2000: 1 trial · 2001: none · 2002: none · 2003: none · 2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: none · 2012: 1 paper, 1 trial · 2013: 1 trial · 2014: none · 2015: 1 paper
Papers 2
- (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
- Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Co-author DOI 10.1002/cncr.27592↗
Trials 5
- Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer Study chair NCT01956812↗
- A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. Study chair NCT01510561↗
- Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer Study chair NCT00603863↗
- Safety and Efficacy Study of 90Y-hPAM4 at Different Doses Study chair NCT00597129↗
- Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer Study chair NCT00041639↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bert H. O’Neil · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- Allyson J. Ocean · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- David M. Goldenberg · 2 shared papers, 2012–2015 · strength 0.06
- Paper (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancre… DOI 10.1016/j.ejca.2015.06.119↗
- Paper Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced panc… DOI 10.1002/cncr.27592↗
- Neeta D. Pandit-Taskar · 1 shared paper, 2015 · strength 0.03
- Alexander Starodub · 1 shared paper, 2015 · strength 0.03
- Fa-Chyi Lee · 1 shared paper, 2015 · strength 0.03
- Donald Richards · 1 shared paper, 2015 · strength 0.03
- Eileen Mary O'Reilly · 1 shared paper, 2015 · strength 0.03
- Ronald Lee Korn · 1 shared paper, 2015 · strength 0.03
- Fadi Braiteh · 1 shared paper, 2015 · strength 0.03
- Ramesh K. Ramanathan · 1 shared paper, 2015 · strength 0.03
- Maeve Aine Lowery · 1 shared paper, 2015 · strength 0.03
- Tomislav Dragovich · 1 shared paper, 2015 · strength 0.03
- Richard C. Frank · 1 shared paper, 2015 · strength 0.03
- Nathan Bahary · 1 shared paper, 2015 · strength 0.03
- Vincent J. Picozzi · 1 shared paper, 2015 · strength 0.03
- Steven J. Cohen · 1 shared paper, 2015 · strength 0.03
- Daniel D. Von Hoff · 1 shared paper, 2015 · strength 0.03
- Seza Güleç · 1 shared paper, 2012 · strength 0.02
- Alberto J. Montero · 1 shared paper, 2012 · strength 0.02
- Tanios Bekaii‐Saab · 1 shared paper, 2012 · strength 0.02
- David V. Gold · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.